Research Article Details
| Article ID: | A19180 |
| PMID: | 29537209 |
| Source: | Pomeranian J Life Sci |
| Title: | Metabolic risk factors of coronary heart disease in relation to anthropometric measures in nonalcoholic fatty liver disease patients following dietary intervention. |
| Abstract: | Introduction: Nonalcoholic fatty liver disease (NAFLD) is connected with high risk of metabolic disorders, such as: metabolic syndrome, type 2 diabetes, dyslipidemia and independently, coronary heart disease (CHD). Materials and methods: A group of 108 Caucasian individuals (39 women and 69 men) aged 20–77 years with NAFLD were prospectively enrolled in the study. The diagnosis of NAFLD was con- 􀏐irmed during the 􀏐irst appointment using ultrasonography. The liver serum tests such as alanine aminotransferase and aspartate aminotransferase levels were taken into account, as well. All of the tests and measurements were taken at the begining and after 6 month of dieting. Anthropometric tools (body mass index – BMI, waist circumference – WC, waist to hip ratio – WHR, waist to height ratio – WHtR, coinicity index – C -Index) were examined in relation to metabolic risk factors of CHD (increased: triacylglycerols, low density lipoprotein, total cholesterol, glycemia and low high density lipoprotein). Results: Statistical signi􀏐icant reduction of body weight, BMI, WC, WHR, WHtR and C -Index (p < 0.05) contributed to the improvement of serum triacylglycerols in both sexes (p < 0.05). Indicators of abdominal obesity (WC, WHR, WHtR, C -Index) correlated signi􀏐icantly with serum glucose (p < 0.05) both before and after the diet and with serum lipids, either before or after the diet (p < 0.05), in both sexes. Conclusions: It seems bene􀏐icial to spread the use of anthropometric tools, especially C -Index and WHtR, in primary health care practice for either early prevention or prediction of metabolic CHD risk occurrence, and its potential fatal consequences among patients with NAFLD or with other metabolic disorders. Keywords: fatty liver disease; cardiovascular disease; risk factors; anthropometry; nutrition; metabolic syndrome. |
| DOI: | 10.21164/pomjlifesci.141 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D080 | Citrulline | Chemical drug | DB00155 | -- | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |